TQB-2101

N/A

Report date: 2025/03/26 15:58:04

Base Information

Drug NameTQB-2101
Drug Alias NameTQB2101TQB-2101
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-Inactive tyrosine-protein kinase transmembrane receptor ROR1
TargetsInactive tyrosine-protein kinase transmembrane receptor ROR1
Therapy Area/IndicationsLung NeoplasmsHematologic NeoplasmsColorectal Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesNanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesNanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group
Inactive CompaniesN/A
Active IndicationsLung NeoplasmsHematologic NeoplasmsColorectal Neoplasms +[4] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A